WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year
WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year
PR Newswire
SHANGHAI, Oct. 19, 2026
SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.
Frost & Sullivan highlighted WuXi AppTec's integrated CRDMO model, which enables the company to support customers across the full drug development lifecycle, from early discovery through commercial manufacturing. The firm noted WuXi AppTec's global capacity, operational consistency, and ability to adapt to increasingly complex modalities as key differentiators.
"WuXi AppTec distinguishes itself through its strong focus on evolving customer needs," said Unmesh Lal, Vice President of Healthcare and Life Sciences at Frost & Sullivan. "Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide."
"We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "As a dedicated enabler of the pharmaceutical industry, we remain committed to our CRDMO strategy and to helping customers around the world bring life-changing therapies to patients faster."
Frost & Sullivan's Company of the Year Recognition is its top honor, recognizing companies that exemplify visionary innovation, market-leading performance, and unmatched customer care.
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.
SOURCE WuXi AppTec
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
United States